SAN

75.67

+0.12%↑

ARGX

757.6

-0.21%↓

SHL.DE

34.6

-1.2%↓

PHIA

22.5

-0.92%↓

FRE

37.32

-0.85%↓

SAN

75.67

+0.12%↑

ARGX

757.6

-0.21%↓

SHL.DE

34.6

-1.2%↓

PHIA

22.5

-0.92%↓

FRE

37.32

-0.85%↓

SAN

75.67

+0.12%↑

ARGX

757.6

-0.21%↓

SHL.DE

34.6

-1.2%↓

PHIA

22.5

-0.92%↓

FRE

37.32

-0.85%↓

SAN

75.67

+0.12%↑

ARGX

757.6

-0.21%↓

SHL.DE

34.6

-1.2%↓

PHIA

22.5

-0.92%↓

FRE

37.32

-0.85%↓

SAN

75.67

+0.12%↑

ARGX

757.6

-0.21%↓

SHL.DE

34.6

-1.2%↓

PHIA

22.5

-0.92%↓

FRE

37.32

-0.85%↓

Strona główna・Stock List・Laboratorios Farmaceuticos Rovi SA
Search

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

58.4 1.04

Buy

Price update 10 cze 2026, 15:24 UTC

BuySell

Overview

Share price change

24h

Current

Min

57.65

Max

58.55

Key metrics

By Trading Economics

Income

-33M

9.5M

Sales

-66M

152M

P/E

Sector Avg

24.641

49.052

EPS

0.185

Profit margin

6.216

Employees

1,950

EBITDA

-45M

18M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+27.78% upside

Dividends

By Dow Jones

Next Earnings

23 lip 2026

Market Stats

By TradingEconomics

Market Cap

-1.1B

3B

Previous open

57.36

Previous close

58.4

News Sentiment

By Acuity

50%

50%

154 / 344 Ranking in Healthcare

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 cze 2026, 23:36 UTC

Earnings

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Read

10 cze 2026, 23:19 UTC

Hot Stocks

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Read

10 cze 2026, 23:09 UTC

Major Market Movers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Read

10 cze 2026, 23:04 UTC

Earnings

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Read

10 cze 2026, 20:44 UTC

Major Market Movers

Caterpillar Raises Quarterly Dividend 8%

DJ

Read

10 cze 2026, 23:49 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Read

10 cze 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Read

10 cze 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Read

10 cze 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Read

10 cze 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Read

10 cze 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Read

10 cze 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Read

10 cze 2026, 21:57 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:52 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:35 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:22 UTC

Earnings

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

10 cze 2026, 20:39 UTC

Market Talk
Earnings

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Read

10 cze 2026, 20:34 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Earnings

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Read

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

27.78% upside

12 Months Forecast

Average 73.6 EUR  27.78%

High 83 EUR

Low 64.2 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Based on 2 analysts giving stock ratings to Laboratorios Farmaceuticos Rovi SA - Dist in the past 3 months.

Sentiment

By Acuity

154 / 344 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Other stocks from the sector

SAN

Sanofi SA

75.67

↑ +0.12%

ARGX

Argenx SE

757.6

↓-0.21%

SHL.DE

Siemens Healthineers AG

34.6

↓-1.2%

PHIA

Koninklijke Philips NV

22.5

↓-0.92%

FRE

Fresenius SE & Co KGaA

37.32

↓-0.85%
help-icon Live chat